Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Nuclear Medicine

  Free Subscription

Articles published in Nuklearmedizin

Retrieve available abstracts of 112 articles:
HTML format

Single Articles

    May 2024
  1. SCHMIDT M, Hohberg M, Felcht M, Kuhn T, et al
    [Nuclear medicine procedure guideline for sentinel lymph node localization].
    Nuklearmedizin. 2024 May 24. doi: 10.1055/a-2319-8306.
    PubMed     Abstract available

  2. HEIDEMANNS S, Trautmann S, Weidt D, Hellwig D, et al
    Update of the competence-based catalog of learning objectives in nuclear medicine for the study of human medicine in Germany.
    Nuklearmedizin. 2024 May 22. doi: 10.1055/a-2319-7549.
    PubMed     Abstract available

    April 2024
  3. WIELENBERG CF, Fostitsch JC, Volz C, Marks R, et al
    FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL).
    Nuklearmedizin. 2024 Apr 9. doi: 10.1055/a-2283-8417.
    PubMed     Abstract available

  4. BOCK F, Frerker B, Schubert L, Rennau H, et al
    Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients.
    Nuklearmedizin. 2024 Apr 5. doi: 10.1055/a-2284-0593.
    PubMed     Abstract available

  5. SAEED S, Dimopoulos I, Begum N, Kroger JR, et al
    [Not Available].
    Nuklearmedizin. 2024;63:78-80.

  6. WERNER R, Haug A, Buske C, Heidegger S, et al
    CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
    Nuklearmedizin. 2024;63:57-61.
    PubMed     Abstract available

    March 2024
  7. GACULA SIG, Kunte SC, Unterrainer LM, Rubenthaler J, et al
    Correction: Divergent growth on [18F]FDG PET/CT in a case of co-existing pulmonary metastatic leiomyosarcoma and papillary thyroid carcinoma.
    Nuklearmedizin. 2024 Mar 25. doi: 10.1055/a-2286-9571.

  8. USLU H, Sahin D, Tatoglu MT, Ibisoglu E, et al
    Growing Teratoma Syndrome Revealed By F-18 FDG PET/CT.
    Nuklearmedizin. 2024 Mar 14. doi: 10.1055/a-2273-2350.

  9. GACULA SIG, Kunte SC, Unterrainer LM, Rubenthaler J, et al
    Divergent growth on [18F]FDG PET/CT in a case of co-existing pulmonary metastatic leiomyosarcoma and papillary thyroid carcinoma.
    Nuklearmedizin. 2024 Mar 11. doi: 10.1055/a-2273-2447.

  10. LIU Y, Tang W, Huang Z
    Correction: 99mTc-MDP Bone Scan and 18F-FDG PET/CT Imaging of Primary Hepatic Osteosarcoma.
    Nuklearmedizin. 2024 Mar 4. doi: 10.1055/a-2275-1035.

    February 2024
  11. CHEN M, Liu Y
    Correction: 18F-FDG PET/CT images of adult pulmonary blastoma: a case report.
    Nuklearmedizin. 2024 Feb 20. doi: 10.1055/a-2265-4049.

  12. AYDAR S, Knobl H, Burchert W, Lindner O, et al
    Diagnostic accuracy of artificial intelligence-enabled vectorcardiography versus myocardial perfusion SPECT in patients with suspected or known coronary heart disease.
    Nuklearmedizin. 2024 Feb 20. doi: 10.1055/a-2263-2322.
    PubMed     Abstract available

  13. CHEN M, Liu Y
    18F-FDG PET/CT images of adult pulmonary blastoma: a case report.
    Nuklearmedizin. 2024 Feb 7. doi: 10.1055/a-2237-8775.

  14. UMUTLU L, Nensa F, Demircioglu A, Antoch G, et al
    Radiomics Analysis of Multiparametric PET/MRI for N- and M-Staging in Patients with Primary Cervical Cancer.
    Nuklearmedizin. 2024;63:34-42.
    PubMed     Abstract available

  15. FISCHER M, Schneider-Eicke J
    Nonosseous bone seeking tracer focal uptake in the conventional scintigraphy.
    Nuklearmedizin. 2024;63:45-47.

  16. DIETLEIN M, Grunwald F, Schmidt M, Kreissl MC, et al
    [Guideline for Radioiodine Therapy for Benign Thyroid Diseases (6/2022 - AWMF No. 031-003)].
    Nuklearmedizin. 2024;63:8-20.
    PubMed     Abstract available

    January 2024
  17. FREUDENBERG R, Kastner D, Kotzerke J, Brogsitter C, et al
    [Evaluation of risk analysis in treatment with unsealed radioactive substances in nuclear medicine].
    Nuklearmedizin. 2024 Jan 23. doi: 10.1055/a-2237-8639.

  18. MAMAN A
    Incidental Papillary Thyroid Carcinoma Detected by Ga-68 DOTATATE PET/CT: A Rare Case Study and Clinical Considerations.
    Nuklearmedizin. 2024 Jan 23. doi: 10.1055/a-2238-4186.

  19. NOURBAKHSH S, Salehi Y, Farzanehfar S, Ghaletaki R, et al
    FAPI PET/CT provides higher uptake and better target to back ground in recurrent and metastatic tumors of patients with Iodine refractory papillary thyroid cancer compared with FDG PET CT.
    Nuklearmedizin. 2024 Jan 8. doi: 10.1055/a-2185-7746.
    PubMed     Abstract available

  20. ARSLANTAS E, Aycicek A, Esen Akkas B, Tahtakesen Gucer TN, et al
    The Role of FDG- PET/CT in Detecting Bone Marrow Involvement in Childhood Solid Tumors.
    Nuklearmedizin. 2024 Jan 8. doi: 10.1055/a-2224-9441.
    PubMed     Abstract available

  21. VURAL TOPUZ O, Bagbudar S
    Cervical Cancer Metastasis to the Stomach Masquerading as Primary Gastric Cancer: A Case Report of a Rare Metastasis Detected via 18F-FDG PET/CT.
    Nuklearmedizin. 2024 Jan 8. doi: 10.1055/a-2224-9673.

  22. SANTO G, Di Santo G, Zelger B, Virgolini I, et al
    Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy.
    Nuklearmedizin. 2024 Jan 8. doi: 10.1055/a-2221-3220.

    December 2023
  23. SERFLING SE, Buck A, Rowe SP, Higuchi T, et al
    Red Bull PET/CT.
    Nuklearmedizin. 2023 Dec 22. doi: 10.1055/a-2195-0138.
    PubMed     Abstract available

  24. ROGASCH JMM, Shi K, Kersting D, Seifert R, et al
    Methodological evaluation of original articles on radiomics and machine learning for outcome prediction based on positron emission tomography (PET).
    Nuklearmedizin. 2023;62:361-369.
    PubMed     Abstract available

  25. WENDLER T, Kreissl MC, Schemmer B, Rogasch JMM, et al
    Artificial Intelligence-powered automatic volume calculation in medical images - available tools, performance and challenges for nuclear medicine.
    Nuklearmedizin. 2023;62:343-353.
    PubMed     Abstract available

  26. HELLWIG D, Hellwig NC, Boehner S, Fuchs T, et al
    Artificial Intelligence and Deep Learning for Advancing PET Image Reconstruction: State-of-the-Art and Future Directions.
    Nuklearmedizin. 2023;62:334-342.
    PubMed     Abstract available

  27. MIEDERER I, Rogasch JMM, Wendler T
    AI in Nuclear Medicine - a review of the current situation.
    Nuklearmedizin. 2023;62:332-333.

    November 2023
  28. LOHMANN P, Bundschuh RA, Miederer I, Mottaghy FM, et al
    Clinical Applications of Radiomics in Nuclear Medicine.
    Nuklearmedizin. 2023 Nov 7. doi: 10.1055/a-2191-3271.
    PubMed     Abstract available

    October 2023
  29. FUCHS T, Kaiser L, Muller D, Papp L, et al
    Enhancing Interoperability and Harmonisation of Nuclear Medicine Image Data and Associated Clinical Data.
    Nuklearmedizin. 2023 Oct 31. doi: 10.1055/a-2187-5701.
    PubMed     Abstract available

  30. RASSEK P, Bobe S, Kies P, Roll W, et al
    The value of core needle biopsy in the diagnostic workup of a [18F]FDG-PET positive thyroid metastasis from colorectal cancer.
    Nuklearmedizin. 2023 Oct 23. doi: 10.1055/a-2178-6908.

  31. BROSCH-LENZ JF, Delker A, Schmidt F, Tran-Gia J, et al
    On the Use of Artificial Intelligence for Dosimetry of Radiopharmaceutical Therapies.
    Nuklearmedizin. 2023 Oct 12. doi: 10.1055/a-2179-6872.
    PubMed     Abstract available

  32. MOON H, Ku EJ, Kim C
    Ectopic Thyroid Tissue in the Uterus Identified by Iodine-131 SPECT/CT.
    Nuklearmedizin. 2023;62:294-295.

  33. KUSTNER T, Hepp T, Seith F
    Multiparametric Oncologic Hybrid Imaging: Machine Learning Challenges and Opportunities.
    Nuklearmedizin. 2023;62:306-313.
    PubMed     Abstract available

    September 2023
  34. DEININGER K, Raacke JN, Yousefzadeh-Nowshahr E, Kropf-Sanchen C, et al
    Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC.
    Nuklearmedizin. 2023 Sep 11. doi: 10.1055/a-2150-4130.
    PubMed     Abstract available

  35. MIEDERER I, Rogasch JMM, Fischer R, Fuchs T, et al
    The Medical Informatics Initiative and the Network University Medicine - Perspectives for Nuclear Medicine.
    Nuklearmedizin. 2023 Sep 8. doi: 10.1055/a-2067-7642.
    PubMed     Abstract available

    August 2023
  36. RASSEK P, Schafers M, Rahbar K, Backhaus P, et al
    [18F]-PSMA-1007-PET for evaluation of kidney function.
    Nuklearmedizin. 2023 Aug 18. doi: 10.1055/a-2127-7880.
    PubMed     Abstract available

  37. KAPLAN I, Kepenek F, Guzel Y, Can C, et al
    The Role of 68Ga FAPI-04 and 18F-FDG PET/CT in Detecting Liver Metastases in Different Types of Cancer.
    Nuklearmedizin. 2023 Aug 18. doi: 10.1055/a-2127-7699.
    PubMed     Abstract available

  38. FROHLICH M, Schmalzing M, Buck A, Bley TA, et al
    PET-Derived Increased Inflammation in Large Vessels is linked to Relapse-Free Survival in Patients with Giant Cell Arteritis.
    Nuklearmedizin. 2023;62:229-234.
    PubMed     Abstract available

    June 2023
  39. LINDNER O, Schaefer WM, Silber S, Rischpler C, et al
    Myocardial Perfusion SPECT and ATTR imaging 2021 in Germany: Results of the 9th Survey.
    Nuklearmedizin. 2023 Jun 2. doi: 10.1055/a-2084-7454.
    PubMed     Abstract available

  40. LAPA C, Rischpler C, Bundschuh RA, Dierks A, et al
    Value of [18F]FDG PET/CT in diagnosis and management of spondylodiscitis.
    Nuklearmedizin. 2023;62:192-199.
    PubMed     Abstract available

  41. CEGLA P, Wojewodzka-Mirocha M, Chalewska W, Dedecjus M, et al
    [68Ga]Ga-PSMA-11 uptake in planepitheliale lung cancer: a pitfall in prostate cancer imaging.
    Nuklearmedizin. 2023;62:220-221.

    April 2023
  42. ZIPPEL C, Antke C, Mori Y, Sombetzki A, et al
    [Breakeven Analysis for Imaging Devices: Basic Introduction with Presentation of a User-Friendly Tool for in-clinic Calculation Using PET/CT as an Example].
    Nuklearmedizin. 2023 Apr 5. doi: 10.1055/a-2036-7694.
    PubMed     Abstract available

  43. EILSBERGER F, Lapa C, Klasner B, Schafers MA, et al
    [Hand in hand - the future of SPECT and PET imaging].
    Nuklearmedizin. 2023;62:52-53.

  44. KARIMIPOURFARD M, Sina S, Khodadai Shoshtari F, Alavi M, et al
    Correction: Synthesis of Prospective Multiple Time Points F-18 FDG PET Images from a Single Scan Using a Supervised Generative Adversarial Network.
    Nuklearmedizin. 2023;62:e1.

    March 2023
  45. KARIMIPOURFARD M, Sina S, Khodadai Shoshtari F, Alavi M, et al
    Synthesis of Prospective Multiple Time Points F-18 FDG PET Images from a Single Scan Using a Supervised Generative Adversarial Network.
    Nuklearmedizin. 2023 Mar 6. doi: 10.1055/a-2026-0784.
    PubMed     Abstract available

  46. LIU Y, Tang W, Huang Z
    99mTc-MDP Bone Scan and 18F-FDG PET/CT Imaging of Primary Hepatic Osteosarcoma.
    Nuklearmedizin. 2023 Mar 6. doi: 10.1055/a-2036-7741.
    PubMed     Abstract available

    February 2023
  47. KERTESZ H, Traub-Weidinger T, Cal-Gonzalez J, Rausch I, et al
    Feasibility of dose reduction for [18F]FDG-PET/MR imaging of patients with non-lesional epilepsy.
    Nuklearmedizin. 2023 Feb 20. doi: 10.1055/a-2015-7785.
    PubMed     Abstract available

  48. LIU H, Yang X, You Z, Hu Z, et al
    Role of 68Ga-FAPI-04 PET/CT in the Initial Staging of Esophageal Cancer.
    Nuklearmedizin. 2023;62:38-44.
    PubMed     Abstract available

  49. ARSLANTAS E, Aycicek A, Akici F, Ozkara S, et al
    Comparison of bone marrow biopsy and fluorodeoxyglucose-positron emission tomography for the assessment of bone marrow infiltration in children with Hodgkin's lymphoma.
    Nuklearmedizin. 2023;62:20-26.
    PubMed     Abstract available

  50. AFSHAR-OROMIEH A, Eiber M, Fendler W, Schmidt M, et al
    [Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT].
    Nuklearmedizin. 2023;62:5-19.
    PubMed     Abstract available

  51. HAPPEL C, Groner D, Kranert WT, Grunwald F, et al
    Evaluation of activity kinetics in breast milk and calculation of the resulting effective radiation dose after 99mTc-MIBI scintigraphy of a breastfeeding women.
    Nuklearmedizin. 2023;62:45-46.
    PubMed     Abstract available

    January 2023
  52. SAHIN YA, Eilsberger F, Einspanner E, Kunz J, et al
    [Is there an unmet need to establish a young talent section "Young DGN" within the German Society of Nuclear Medicine (DGN)? - Results of a 2021/2022 web-based survey among German Nuclear Medicine professionals].
    Nuklearmedizin. 2023 Jan 27. doi: 10.1055/a-1984-8116.
    PubMed     Abstract available

  53. KNAPPE LM, Verburg FA, Giovanella L, Luster M, et al
    Diagnostic value of FDG-PET/CT in the diagnostic work-up of inflammation of unknown origin.
    Nuklearmedizin. 2023 Jan 9. doi: 10.1055/a-1976-1765.
    PubMed     Abstract available

  54. NAZERANI-ZEMANN T, Stanzel S, Gstettner C, Aigner RM, et al
    F18-FDG PET/CT in a patient with Antisynthetase Syndrome.
    Nuklearmedizin. 2023 Jan 4. doi: 10.1055/a-1996-0157.
    PubMed     Abstract available

    December 2022
  55. NEUBERGER M, Dropmann JA, Kleespies A, Fuerst H, et al
    Determinants and clinical significance of negative scintigraphic findings in primary hyperparathyroidism: a retrospective observational study.
    Nuklearmedizin. 2022;61:440-448.
    PubMed     Abstract available

    October 2022
  56. SCHEER C, Juptner M, Maier T, Lutzen U, et al
    Unusual accumulation of 177Lu-DOTATATE at the injection site of a COVID-19 vaccination.
    Nuklearmedizin. 2022;61:410-413.

  57. SCHENKE SA, Kreissl MC, Grunert M, Hach A, et al
    Distribution of Functional Status of Thyroid Nodules and Malignancy Rates of Hyperfunctioning and Hypofunctioning Thyroid Nodules in Germany.
    Nuklearmedizin. 2022;61:376-384.
    PubMed     Abstract available

    August 2022
  58. GUGGENBERGER KV, Vogt ML, Rowe SP, Higuchi T, et al
    Clinical Utility of C-Reactive Protein and White Blood Cell Count for Scheduling an [18F]FDG PET/CT in Patients with Giant Cell Arteritis.
    Nuklearmedizin. 2022 Aug 17. doi: 10.1055/a-1830-7767.
    PubMed     Abstract available

  59. FREUDENBERG LS, Freudenberg BJ, Klett R, Herrmann K, et al
    [Nuclear Medicine Physicians: A threatened species?]
    Nuklearmedizin. 2022 Aug 17. doi: 10.1055/a-1907-4122.

  60. AGULOGLU N, Aksu A, Akyol M, Katgi N, et al
    Nuklearmedizin. 2022 Aug 17. doi: 10.1055/a-1868-4918.
    PubMed     Abstract available

  61. KREBOLD AK, Schaller T, Appenzeller M, Schwaiblmair M, et al
    [18F]FDG PET/CT guided biopsy confirms diagnosis of granulomatosis with polyangiitis.
    Nuklearmedizin. 2022 Aug 17. doi: 10.1055/a-1907-4248.

  62. EILSBERGER F, Luster M, Librizzi D, Rodepeter F, et al
    Medullary Thyroid Carcinoma presenting as an Incidentaloma on Gallium-68-PSMA-PET/CT - Systematic Literature Review and Case Report.
    Nuklearmedizin. 2022 Aug 11. doi: 10.1055/a-1896-0106.

  63. KUGLER A, Kuwert T, Ritt P, Grings A, et al
    Influence of CT metal artifact reduction on SPECT/CT quantification of bone scintigraphy - Retrospective study for selected types of metal implants.
    Nuklearmedizin. 2022 Aug 9. doi: 10.1055/a-1883-9281.
    PubMed     Abstract available

  64. ABOUZIAN S, Camacho V, Sabate A, Stefaneli P, et al
    Audiovisual intervention alleviates anxiety of patients during PET/CT imaging.
    Nuklearmedizin. 2022;61:301-307.
    PubMed     Abstract available

    July 2022
  65. BEINDORFF N, Papadopoulos N, Hoffmann S, Mohan AM, et al
    Monitoring orthodontic tooth movement in rats after piezocision by bone scintigraphy.
    Nuklearmedizin. 2022 Jul 27. doi: 10.1055/a-1816-6825.
    PubMed     Abstract available

  66. HOLZGREVE A, Eilsberger F, Einspanner E, Kunz J, et al
    [The Youngsters of the German Society of Nuclear Medicine (Young DGN)].
    Nuklearmedizin. 2022 Jul 11. doi: 10.1055/a-1866-3000.

  67. HESCHELER DA, Stegger L, Schlack K, Bogemann M, et al
    Discrepancy of PSMA PET imaging and bone scan showing limited value of bone scan and CT in evaluation of extent of bone involvement.
    Nuklearmedizin. 2022 Jul 11. doi: 10.1055/a-1809-4570.

    June 2022
  68. ZHANG R, Hohenforst-Schmidt W, Steppert C, Sziklavari Z, et al
    Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naive patients with non-small cell lung cancer.
    Nuklearmedizin. 2022 Jun 29. doi: 10.1055/a-1816-6950.
    PubMed     Abstract available

  69. TULIPAN AJ, Guzman AJ, Haslerud TM, Foldnes K, et al
    Enhancing PSMA-PET/CT with intravenous contrast: Improved tracer clearance in the prostate bed.
    Nuklearmedizin. 2022 Jun 14. doi: 10.1055/a-1821-8112.
    PubMed     Abstract available

  70. KURTH J, Potratz M, Heuschkel M, Krause BJ, et al
    GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals.
    Nuklearmedizin. 2022;61:247-261.
    PubMed     Abstract available

    April 2022
  71. SCHMIDT M, Bartenstein P, Bucerius J, Dietlein M, et al
    Correction: Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine.
    Nuklearmedizin. 2022 Apr 27. doi: 10.1055/a-1824-1280.

  72. FREUDENBERG R, Hesse L, Kotzerke J
    [Evaluation of radionuclide impurities in several radiopharmaceuticals].
    Nuklearmedizin. 2022 Apr 14. doi: 10.1055/a-1759-1815.
    PubMed     Abstract available

  73. WANKE C, Szemerski B, Geworski L
    [Incorporation Monitoring of Staff using I-131 and Lu-177 in a Nuclear Medicine Ward].
    Nuklearmedizin. 2022 Apr 6. doi: 10.1055/a-1759-1940.
    PubMed     Abstract available

  74. RINSCHEID A, Janzen T, Alikhani B, Beer AJ, et al
    Radiation doses from low-dose CT scans in SPECT/CT and PET/CT examinations: A survey in Germany.
    Nuklearmedizin. 2022 Apr 6. doi: 10.1055/a-1759-3900.
    PubMed     Abstract available

  75. MULLER PJ, Dietlein M, Kobe C, Heidenreich A, et al
    Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy - Experience at a tertiary referral center.
    Nuklearmedizin. 2022 Apr 6. doi: 10.1055/a-1697-8111.
    PubMed     Abstract available

  76. EILSBERGER F, Girmond C, Boekhoff J, Librizzi D, et al
    [High clinical value of bone scintigraphy as a staging method for breast cancer].
    Nuklearmedizin. 2022 Apr 6. doi: 10.1055/a-1780-8378.
    PubMed     Abstract available

  77. USLU H, Orhan Varoglu A, Tatoglu MT, Kilicaslan E, et al
    A Case of Chorea-Acanthocytosis with FDG PET/CT Imaging.
    Nuklearmedizin. 2022 Apr 6. doi: 10.1055/a-1780-8463.

  78. LENGANA T, Lawal I, Janse Van Rensburg C, Mokoala K, et al
    The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.
    Nuklearmedizin. 2022;61:120-129.
    PubMed     Abstract available

  79. SCHMIDT M, Decarolis B, Franzius C, Hero B, et al

    Nuklearmedizin. 2022;61:96-110.

    March 2022
  80. SCHMIDT M, Bartenstein P, Bucerius J, Dietlein M, et al
    Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine.
    Nuklearmedizin. 2022 Mar 17. doi: 10.1055/a-1783-8154.
    PubMed     Abstract available

    February 2022
  81. BOSWIJK E, de Ligt M, Habets MJ, Mingels AMA, et al
    Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trial.
    Nuklearmedizin. 2022;61:33-41.
    PubMed     Abstract available

  82. KOUKALOVA R, Vasina J, Stika J, Doubek M, et al
    Aggressive systemic mastocytosis with diffuse bone marrow 18F-FDG uptake.
    Nuklearmedizin. 2022;61:58-61.
    PubMed     Abstract available

    January 2022
  83. PARK SB, Lim CH, Chang WH, Hwang JH, et al
    Correction: Diagnostic Value of Bone SPECT/CT Using 99mTc-Methylene Diphosphonate in Patients with Unspecified Chest Wall Pain.
    Nuklearmedizin. 2022 Jan 21. doi: 10.1055/a-1728-8828.

  84. ROWE SP, Buck A, Bundschuh RA, Lapa C, et al
    [18F]DCFPyL PET/CT for Imaging of Prostate Cancer.
    Nuklearmedizin. 2022 Jan 14. doi: 10.1055/a-1659-0010.
    PubMed     Abstract available

    December 2021
  85. NAM HY, Seo S, Lee MJ, Kim K, et al
    No association of Brain-derived neurotrophic factor with striatal dopamine transporter availability in healthy subjects.
    Nuklearmedizin. 2021;60:434-437.
    PubMed     Abstract available

  86. BERLINER C, Boss K, Pape A, Kribben A, et al
    [Oldies (but Goldies): Peritoneal Scintigraphy in Chronic Peritoneal Dialysis Patients].
    Nuklearmedizin. 2021;60:450-453.

    November 2021
  87. RADZIKOWSKI KC, Rendl G, Beheshti M, Pirich C, et al
    18F Choline PET/CT in a patient with HRPT2 mutation: Detecting parathyroid carcinoma recurrence and concomitant breast carcinoma.
    Nuklearmedizin. 2021 Nov 29. doi: 10.1055/a-1670-9315.

  88. PARK SB, Lim CH, Chang WH, Hwang JH, et al
    Diagnostic Value of Bone SPECT/CT Using 99mTc-Methylene Diphosphonate in Patients with Unspecified Chest Wall Pain.
    Nuklearmedizin. 2021 Nov 12. doi: 10.1055/a-1549-5910.
    PubMed     Abstract available

    October 2021
    Alpha emitting nuclides in nuclear medicine theranostics.
    Nuklearmedizin. 2021 Oct 8. doi: 10.1055/a-1650-9995.
    PubMed     Abstract available

  90. ROGASCH JMM, Penzkofer T
    AI in nuclear medicine - what, why and how?
    Nuklearmedizin. 2021;60:321-324.

    September 2021
  91. STOLZENBACH LF, Locherbach F, Wargenau K, Pose R, et al
    Correction: Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities.
    Nuklearmedizin. 2021 Sep 3. doi: 10.1055/a-1626-6669.

  92. FARAG S, IJzerman NS, Houdijk MPM, Reyners AKL, et al
    Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent.
    Nuklearmedizin. 2021 Sep 3. doi: 10.1055/a-1542-6211.
    PubMed     Abstract available

    August 2021
  93. STOLZENBACH LF, Locherbach F, Wargenau K, Pose R, et al
    Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities.
    Nuklearmedizin. 2021 Aug 20. doi: 10.1055/a-1542-6064.
    PubMed     Abstract available

  94. POETZSCH S, Brenner W, Spreckelmeyer S
    Are radiopharmaceuticals self-sterilizing? Radiation effect of gallium-68 and lutetium-177 on bacillus pumilus and staphylococcus succinus.
    Nuklearmedizin. 2021 Aug 20. doi: 10.1055/a-1547-0628.
    PubMed     Abstract available

  95. YANG X, You Z, Chen Y, Dai T, et al
    Thymic squamous cell carcinoma mimicking lymphoma on 68Ga-FAPI PET/CT.
    Nuklearmedizin. 2021 Aug 17. doi: 10.1055/a-1561-2014.

  96. BECK MT, Rugel G, Reinfelder J, Kuwert T, et al
    Quantitative Analysis of Multimodal Skeletal SPECT/CT Reconstructions in Diagnosing Medication-related Osteonecrosis of the Jaw.
    Nuklearmedizin. 2021 Aug 11. doi: 10.1055/a-1525-7621.
    PubMed     Abstract available

  97. PATT M, Bengel F, Essler M, Krause BJ, et al
    [Fireside chat " section sign 13 (2b) AMG in nuclear medicine therapy" - a follow-up event of NuklearMedizin 2020 - Digital].
    Nuklearmedizin. 2021;60:262-263.

  98. Nuklearmedizin. 2021;60:305.

  99. MIRZAEI S, Prior JO, Farsad M, Lipp RW, et al
    Ausbildung in Nuklearmedizin und Zukunftsperspektiven.
    Nuklearmedizin. 2021;60:264-265.

  100. SUI S, Hou Y
    Assessing Doxorubicin-Induced Cardiomyopathy by 99mTc-3PRGD2 Scintigraphy Targeting Integrin alphavbeta3 in a Rat Model.
    Nuklearmedizin. 2021;60:289-298.
    PubMed     Abstract available

    July 2021
  101. LAPA C, Nestle U, Albert NL, Baues C, et al
    Value of PET imaging for radiation therapy.
    Nuklearmedizin. 2021 Jul 14. doi: 10.1055/a-1525-7029.
    PubMed     Abstract available

  102. KREPPEL B, Gonzalez-Carmona MA, Feldmann G, Kuppers J, et al
    Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.
    Nuklearmedizin. 2021 Jul 13. doi: 10.1055/a-1521-8604.
    PubMed     Abstract available

  103. SAHIN O, Kaya B, Aydin Z, Sen AE, et al
    Prostate incidentaloma on 18F-fluorodeoxyglucose positron emission tomography: Diagnostic value of volumetric positron emission tomography parameters.
    Nuklearmedizin. 2021 Jul 9. doi: 10.1055/a-1525-7607.
    PubMed     Abstract available

    June 2021
  104. OBMANN VC, Grosse-Hokamp N, Alberts I, Fulton N, et al
    Diagnosis and staging of hepatobiliary malignancies: Potential incremental value of (18)F-FDG-PET/MRI compared to MRI of the liver.
    Nuklearmedizin. 2021 Jun 8. doi: 10.1055/a-1486-3671.
    PubMed     Abstract available

  105. HELLWIG D
    Hope for new developments in the reimbursement of oncological PET/CT in Germany.
    Nuklearmedizin. 2021;60:205-208.

  106. FREUDENBERG LS, Klett R, Fischer M, Boddenberg-Patzold B, et al
    [RSO in clinical practice: Status in Germany 2020].
    Nuklearmedizin. 2021;60:224-232.
    PubMed     Abstract available

    April 2021
  107. BARENFANGER F, Block A, Schmelz D, Hamami-Arlinghaus M, et al
    Individual calculation of perfusion activity based on ventilation efficiency for V/P-SPECT.
    Nuklearmedizin. 2021 Apr 16. doi: 10.1055/a-1429-1832.
    PubMed     Abstract available

  108. TATOGLU MT, Uslu H, Ibisoglu E
    The value of (18)F-FDG PET/CT in Diagnosis and Evaluation of Response to Treatment in Retroperitoneal Fibrosis.
    Nuklearmedizin. 2021 Apr 9. doi: 10.1055/a-1429-2237.

  109. FREUDENBERG LS, Essler M, Herrmann K
    [Impact of COVID-19 on Nuclear Medicine Procedures in Germany 2020 - Results of a National Survey].
    Nuklearmedizin. 2021 Apr 1. doi: 10.1055/a-1446-7641.
    PubMed     Abstract available

  110. Nuklearmedizin. 2021;60:76-77.

  111. PEKTOR S, Lawaczeck L, Tenzer S, Bausbacher N, et al
    Characterization of activation induced [18]F-FDG uptake in Dendritic Cells.
    Nuklearmedizin. 2021;60:90-98.
    PubMed     Abstract available

    February 2021

  112. Nuklearmedizin. 2021;60:59-63.

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge.